News

January 16, 2015January 16, 2015

Lower Socioeconomic Status Associated With Rheumatoid Arthritis Treatment Delay, Study Shows

A new study entitled “Association of Socioeconomic Status with Treatment Delays, Disease Activity, Joint Damage and Disability in Rheumatoid Arthritis” was published in Arthritis Care & Research by Emily Molina ... Read more

January 15, 2015January 16, 2015

Infinity Announces Phase 2 Results of Duvelisib for Rheumatoid Arthritis

News

Infinity Pharmaceuticals, Inc., a biopharmaceutical company focused on developing small molecule medicines that target disease pathways in difficult-to-treat diseases, recently announced clinical findings from a Phase II study, dubbed ASPIRA. The trial ... Read more

January 14, 2015January 14, 2015

Health Canada Approves Generic Celebrex for Arthritis Pain Management

News

The governing body responsible for public health in Canada, Health Canada, has announced the approval of a generic version of the medication Celebrex, for the symptomatic relief of pain and inflammation associated with ... Read more

January 13, 2015January 13, 2015

Adalimumab’s First Biosimilar is Launched by Indian Pharmaceutical Company

News

Zydus Cadila launched the world’s first biosimilar of Adalimumab (Enbrel), the largest selling therapy in the world. This event increases the possibility that the up to 12 million people with immune disorders ... Read more

January 12, 2015January 12, 2015

Rheumatoid Arthritis Patients More Likely to Get Infection with Biological DMARDs

News

Risk of adverse events, such as infection and lymphoma, were found to be higher in patients with Rheumatoid Arthritis (RA) treated with biological Disease-modifying antirheumatic drugs, according to a study, entitled, ... Read more

January 9, 2015January 9, 2015

Combined Cytokine Inhibition More Effective in Rheumatoid Arthritis Inflammation

News

A combination of specific cytokine inhibitors was shown to be effective as a potential treatment for patients with Rheumatoid Arthritis (RA). These findings were derived from a study, entitled, “Combined ... Read more

January 8, 2015January 8, 2015

Irvine Stem Cell Treatment Center Offers Free Stem Cell Seminars, Featuring Applications in Rheumatoid Arthritis Treatment

News

Free public seminars on the use of adult stem cells for several degenerative and inflammatory conditions, such as rheumatoid arthritis, are being offered by the Irvine Stem Cell Treatment Center throughout January. The ... Read more

January 7, 2015January 7, 2015

Antibody Levels Predict Mortality in Early Rheumatoid Arthritis

News

In inflammatory arthritis, autoantibodies rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA) have been associated with poor outcomes, such as increased disease activity, radiographic progression and disability. A new study ... Read more

January 6, 2015January 6, 2015

Rheumatoid Arthritis Drug Rituximab Delays Need For Re-treatment from Disease Flares

News

According to recent findings, patients with rheumatoid arthritis (RA) who were treated with rituximab benefit from a delayed need for re-treatment due of a disease flare, which is a common occurrence in chronic diseases such as RA. ... Read more

January 5, 2015January 5, 2015

Can-Fite Designs Rheumatoid Arthritis Phase III Trial of Potent Anti-Inflammatory Drug

News

Can-Fite BioPharma Ltd. completed the design of its Phase III study for CF101, an experimental Rheumatoid Arthritis therapy , according to a recent press release. CF101, commercially known as IB-MECA, is a ... Read more